Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17255692 | ANTIBODY BINDING TO CHONDROITIN SULFATE PROTEOGLYCAN 5 | December 2020 | January 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17255784 | ANTIBODY BINDING TO CELL ADHESION MOLECULE 3 | December 2020 | September 2023 | Allow | 32 | 1 | 0 | No | No |
| 17253584 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | December 2020 | June 2024 | Abandon | 42 | 2 | 0 | No | No |
| 15733838 | COMPOSITIONS AND USES THEREOF FOR TREATING DISEASE OR CONDITION | November 2020 | January 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17058446 | METHODS AND COMPOSITIONS FOR PERTUSSIS DIAGNOSIS | November 2020 | October 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 17057607 | A NOVEL ANTI-CD3/ANTI-CD20 BISPECIFIC ANTIBODY | November 2020 | June 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17098790 | METHOD OF INHIBITING THE GROWTH OF LIVER CANCER CELLS, AND METHOD OF TREATING LIVER CANCER | November 2020 | March 2024 | Abandon | 40 | 2 | 0 | Yes | No |
| 17054469 | ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF | November 2020 | December 2023 | Allow | 37 | 2 | 0 | No | No |
| 17053346 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | November 2020 | May 2024 | Allow | 43 | 1 | 0 | No | No |
| 17052817 | COMBINED THERAPY WITH ICOS BINDING PROTEINS AND ARGININEMETHYLTRANSFERASE INHIBITORS | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17052606 | COMBINATION OF A TYPE II PROTEIN ARGININE METHYLTRANSFERASE INHIBITOR AND AN ICOS BINDING PROTEIN TO TREAT CANCER | November 2020 | January 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17050064 | OPTIMIZED ANTI-TL1A ANTIBODIES | October 2020 | September 2024 | Abandon | 47 | 1 | 0 | No | No |
| 17049800 | Potent Zika Virus-Specific and Cross-Neutralizing Monoclonal Antibodies to Zika and Dengue Viruses Following Zikv Infection or Vaccination | October 2020 | September 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 17066897 | TGF�R1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | October 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17044524 | LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) BINDING ANTIBODY AND USE THEREOF | October 2020 | August 2023 | Allow | 34 | 1 | 0 | No | No |
| 17042806 | P2RX7 MODULATORS IN THERAPY | September 2020 | November 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 17033516 | SYNTHETIC ANTI-PLAGUE ANTIBODIES | September 2020 | May 2023 | Allow | 31 | 1 | 0 | No | No |
| 17021223 | Anti-CD39 Antibody Compositions and Methods | September 2020 | January 2023 | Allow | 28 | 0 | 0 | Yes | No |
| 16979839 | CAR-CD30 T CELLS FOR TREATMENT OF CD30+ TUMORS | September 2020 | May 2023 | Allow | 32 | 1 | 0 | No | No |
| 16978198 | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO HUMAN PLASMALEMMA VESICLE-ASSOCIATED PROTEIN PV-1, PREPARATION AND USE THEREOF | September 2020 | March 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 16970332 | FOXP3 TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY | August 2020 | January 2024 | Abandon | 41 | 1 | 0 | No | No |
| 16992412 | CANINE ANTIBODY THERAPEUTIC FOR TREATING CANCER | August 2020 | December 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16966073 | BISPECIFIC ANTIBODIES COMPRISING AN ANTIGEN-BINDING SITE BINDING TO LAG3 | July 2020 | June 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16964471 | CHIMERIC ANTIGEN RECEPTORS AND METHODS FOR REDUCING TOXICITY | July 2020 | February 2023 | Allow | 31 | 1 | 0 | No | No |
| 16896784 | ANTI-CD38 ANTIBODIES AND FORMULATIONS | June 2020 | January 2023 | Allow | 31 | 0 | 1 | Yes | No |
| 16476487 | ANTI-5T4 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | July 2019 | February 2023 | Allow | 43 | 1 | 1 | Yes | No |
| 16265206 | METHODS AND COMPOSITIONS FOR IMAGING AMYLOID DEPOSITS | February 2019 | February 2024 | Allow | 60 | 6 | 0 | No | No |
| 16078813 | ANTI-CD11D ANTIBODIES AND USES THEREOF | August 2018 | October 2023 | Allow | 60 | 1 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ESSEX, LAURA ANN works in Art Unit 1649 and has examined 28 patent applications in our dataset. With an allowance rate of 67.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner ESSEX, LAURA ANN's allowance rate of 67.9% places them in the 31% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by ESSEX, LAURA ANN receive 1.18 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ESSEX, LAURA ANN is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +41.7% benefit to allowance rate for applications examined by ESSEX, LAURA ANN. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.